AFM
ALPN

Anson Funds Management’s Alpine Immune Sciences Inc ALPN Stock Holding History

Anson Funds Management’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-47,072
Closed -$422K – 85
2016
Q4 		$422K Buy
+47,072
New +$938K 0.13% 45

Other funds holding ALPN

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SIM
Spark Investment Management New York $51.2M AUM 87.14% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

Anson Funds Management's ALPN Position: Q1 2017 in Review

Anson Funds Management sold out of Alpine Immune Sciences Inc (ALPN) in Q1 2017, closing a stake of 47,072 shares — an estimated $422K sold.

Anson Funds Management first reported a position in ALPN in Q4 2016 and held it in 1 quarter. The position peaked at $422K in Q4 2016. 28 funds tracked by Wall St. Rank hold ALPN as of Q1 2017.

  • Anson Funds Management reported no remaining Alpine Immune Sciences Inc position as of Q1 2017 after selling out during the quarter.
  • Anson Funds Management sold 47,072 Alpine Immune Sciences Inc shares in Q1 2017, an estimated $422K.
  • Anson Funds Management first reported a position in Alpine Immune Sciences Inc in Q4 2016 and held it in 1 quarter.
  • Anson Funds Management's Alpine Immune Sciences Inc position peaked at $422K in Q4 2016.
  • 28 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q1 2017.

Based on Anson Funds Management's 13F filing for Q1 2017, filed 15 May 2017.